Showing 1 - 7 results of 7 for search 'Dirk M. Wuttge', query time: 0.04s Refine Results
  1. 1
    Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study

    Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation—a prospective, observational study by Kristofer Andréasson, Karl Neringer, Dirk M. Wuttge, Dan Henrohn, Jan Marsal, Roger Hesselstrand

    Published 2020-10-01
    Get full text
    Article
  2. 2
    Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study

    Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study by Tom Gyllenhammar, Mikael Kanski, Henrik Engblom, Dirk M. Wuttge, Marcus Carlsson, Roger Hesselstrand, Håkan Arheden

    Published 2018-01-01
    Get full text
    Article
  3. 3
    Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment

    Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment by Clara Hjalmarsson, Barbro Kjellström, Kjell Jansson, Magnus Nisell, David Kylhammar, Mohammad Kavianipour, Göran Rådegran, Stefan Söderberg, Gerhard Wikström, Dirk M. Wuttge, Roger Hesselstrand

    Published 2021-08-01
    Get full text
    Article
  4. 4
    The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes.

    The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. by Timothy R D J Radstake, Lenny van Bon, Jasper Broen, Anila Hussiani, Roger Hesselstrand, Dirk M Wuttge, Yanhui Deng, Robbert Simms, Erik Lubberts, Robert Lafyatis

    Published 2009-06-01
    Get full text
    Article
  5. 5
    Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study

    Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study by Viggo Hamberg, Azita Sohrabian, Elizabeth R. Volkmann, Marie Wildt, Anna Löfdahl, Dirk M. Wuttge, Roger Hesselstrand, Göran Dellgren, Gunilla Westergren-Thorsson, Johan Rönnelid, Kristofer Andréasson

    Published 2023-09-01
    Get full text
    Article
  6. 6
    An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

    An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod by Roger Hesselstrand, Jörg H. W. Distler, Gabriela Riemekasten, Dirk M. Wuttge, Marie Törngren, Helén C. Nyhlén, Fredrik Andersson, Helena Eriksson, Birgitta Sparre, Helén Tuvesson, Oliver Distler

    Published 2021-07-01
    Get full text
    Article
  7. 7
    Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic Sclerosis.

    Metabolic Profiling of Systemic Lupus Erythematosus and Comparison with Primary Sjögren's Syndrome and Systemic Sclerosis. by Anders A Bengtsson, Johan Trygg, Dirk M Wuttge, Gunnar Sturfelt, Elke Theander, Magdalena Donten, Thomas Moritz, Carl-Johan Sennbro, Frida Torell, Christian Lood, Izabella Surowiec, Stefan Rännar, Torbjörn Lundstedt

    Published 2016-01-01
    Get full text
    Article

Search Tools: